FDA
approval
· 2020-01-27
FDA Approved: TRIJARDY XR — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
The FDA approved TRIJARDY XR, a fixed-dose combination tablet of empagliflozin, linagliptin, and metformin hydrochloride, in an original application. This provi…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
ORIG AP for TRIJARDY XR (EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE)